Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...

Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many eligible ...

Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors.

A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer Study conducted with ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

The MarketWatch News Department was not involved in the creation of this content. -- Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 ...

This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced ...